Probiotics: A new way to fight bacterial pulmonary infections?

Medecine et Maladies Infectieuses

Volumn 44, Issue 1, 2014, Pages 9-17

  Alexandre, Y ^a   Le Blay, G ^b   Boisrame Gastrin S ^a   Le Gall, F ^a,c   Hery Arnaud G ^a,c   Gouriou, S ^a   Vallet, S ^a,c   Le Berre, R ^a,c  

^a UNIVERSITÉ DE BREST   (France)

^b INSTITUT UNIVERSITAIRE EUROPÉEN DE LA MER   (France)

^c BREST UNIVERSITY HOSPITAL   (France)

Author keywords

Cystic fibrosis; Hospital acquired pneumonia; Immunomodulation; Probiotics

Indexed keywords

ERGYPHILUS; PLACEBO; PROBIOTIC AGENT; SYNBIOTIC 2000 FORTE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANTIMICROBIAL ACTIVITY; BACTERIAL CLEARANCE; BACTERIAL FLORA; BACTERIAL INFECTION; BIFIDOBACTERIUM BIFIDUM; COMMUNITY ACQUIRED PNEUMONIA; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG INDICATION; DRUG MECHANISM; DRUG USE; HUMAN; IMMUNOMODULATION; INTENSIVE CARE; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; LEUCONOSTOC; LEUCONOSTOC MESENTEROIDES; LUNG INFECTION; MORTALITY; NONHUMAN; PEDIOCOCCUS PENTOSACEUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; UPPER RESPIRATORY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

CYSTIC FIBROSIS; HOSPITAL-ACQUIRED PNEUMONIA; IMMUNOMODULATION; MUCOVISCIDOSE; PNEUMONIES NOSOCOMIALES; PROBIOTICS; PROBIOTIQUES;

ANIMALS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; CYSTIC FIBROSIS; DISEASE SUSCEPTIBILITY; DOUBLE-BLIND METHOD; HUMANS; IMMUNE SYSTEM; MICE; MICROBIOTA; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; PROBIOTICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUORUM SENSING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY SYSTEM; SPECIES SPECIFICITY;

EID: 84892543629     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2013.05.001     Document Type: Review

References (53)

1. Carlet D., Collignon P., Goldmann D., Goossens H., Gyssens I.C., Harbarth S., et al. Society's failure to protect a precious resource: antibiotics. Lancet 2011, 378:369-371.
2. Fernandes P. Antibacterial discovery and development-the failure of success?. Nat Biotechnol 2006, 24:1497-1503.
3. Round J.L., Mazmanian S.K. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009, 9:313-323.
4. Oelschlaeger T.A. Mechanisms of probiotic actions-A review. Int J Med Microbiol 2010, 300:57-62.
5. Reid G., Friendship R. Alternatives to antibiotic use: probiotics for the gut. Anim Biotechnol 2002, 13:97-112.
6. Araya M., Morelli L., Reid G., Sanders M.E., Stanton C., Pineiro M., et al. Guidelines for the evaluation of probiotics in food. FAO/WHO Work Group Rep 2002, 1-11.
7. Charlson E.S., Bittinger K., Haas A.R., Fitzgerald A.S., Frank I., Yadav A., et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011, 184:957-963.
8. Zaura E., Keijser B.J.F., Huse S.M., Crielaard W. Defining the healthy "core microbiome" of oral microbial communities. BMC Microbiol 2009, 9:259.
9. Bousbia S., Papazian L., Saux P., Forel J.M., Auffray D.P., Martin C., et al. Repertoire of intensive-care unit pneumonia microbiota. PloS one 2012, 7:e32486.
10. Cox M.J., Allgaier M., Taylor B., Baek M.S., Huang Y.J., Daly R.A., et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PloS one 2010, 5:e11044.
11. Willner D., Furlan M., Haynes M., Schmieder R., Angly F.E., Silva D., et al. Metagenomic analysis of respiratory tract DNA viral communities in cystic fibrosis and non-cystic fibrosis individuals. PloS one 2009, 4:e7370.
12. Sze M.A., Dimitriu P.A., Hayashi S., Elliott W.M., McDonough J.E., Gosselink D.V, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:1073-1080.
13. Schlee M., Wehkamp D., Altenhoefer A., Oelschlaeger T.A., Stange E.F., Fellermann K. Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun 2007, 75:2399-2407.
14. Harata G., He F., Hiruta N., Kawase M., Kubota A., Hiramatsu M., et al. Intranasal administration of Lactobacillus rhamnosus GG protects mice from H1N1 influenza virus infection by regulating respiratory immune responses. Lett Appl Microbiol 2010, 50:597-602.
15. Racedo S., Villena D., Medina M., Agüero G., Rodríguez V., Alvarez S. Lactobacillus casei administration reduces lung injuries in a Streptococcus pneumoniae infection in mice. Microbes Infect 2006, 8:2359-2366.
16. Walker W.A. Mechanisms of action of probiotics. Clin Infect Dis 2008, 46(Suppl. 2):S87-S91.
17. Guglielmetti S., Taverniti V., Minuzzo M., Arioli S., Zanoni I., Stuknyte M., et al. A dairy bacterium displays in vitro probiotic properties for the pharyngeal mucosa by antagonizing group A streptococci and modulating the immune response. Infect Immun 2010, 78:4734-4743.
18. Snydman D.R. The safety of probiotics. Clin Infect Dis 2008, 46(Suppl. 2):S104-S111.
19. Husni R.N., Gordon S.M., Washington J.A., Longworth D.L. Lactobacillus bacteremia and endocarditis: review of 45 cases. Clin Infect Dis 1997, 25:1048-1055.
20. Cannon J.P., Lee T.A., Bolanos J.T., Danziger L.H. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis 2005, 24:31-40.
21. Tannock G.W. Conjugal transfer of plasmid pAM beta 1 in Lactobacillus reuteri and between lactobacilli and Enterococcus faecalis. Appl Environ Microbiol 1987, 53:2693-2695.
22. Haug M.C., Tanner S.A., Lacroix C., Stevens M.J.A., Meile L. Monitoring horizontal antibiotic resistance gene transfer in a colonic fermentation model. FEMS Microbiol Ecol 2011, 78:210-219.
23. Klein G., Hallmann C., Casas I.A., Abad D., Louwers D., Reuter G. Exclusion of vanA, vanB and vanC type glycopeptide resistance in strains of Lactobacillus reuteri and Lactobacillus rhamnosus used as probiotics by polymerase chain reaction and hybridization methods. J Appl Microbiol 2000, 89:815-824.
24. Hao Q., Lu Z., Dong B.R., Huang C.Q., Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 2011, CD006895.
25. Alfaleh K., Anabrees D., Bassler D., Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2011, 16:CD005496.
26. Goldin B.R., Gorbach S.L. Clinical indications for probiotics: an overview. Clin Infect Dis 2008, 46(Suppl. 2):S96-S100.
27. Reid G., Jass D., Sebulsky M.T., McCormick J.K. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003, 16:658-672.
28. de Vrese M., Marteau P.R. Probiotics and prebiotics: effects on diarrhea. J Nutr 2007, 137:803S-8011S.
29. Falagas M.E., Betsi G.I., Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect 2007, 13:657-664.
30. Forsythe P. Probiotics and lung diseases. Chest 2011, 139:901-908.
31. Popova M., Molimard P., Courau S., Crociani D., Dufour C., Le Vacon F., et al. Beneficial effects of probiotics in upper respiratory tract infections and their mechanical actions to antagonize pathogens. J Appl Microbiol 2012, 113:1305-1318.
32. Wolvers D., Antoine D.-M., Myllyluoma E., Schrezenmeir D., Szajewska H., Rijkers G.T. Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics. J Nutr 2010, 140:698S-712S.
33. Siempos I.I., Ntaidou T.K., Falagas M.E. Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med 2010, 38:954-962.
34. Cohen R., Martin E., de La Rocque F., Thollot F., Pecquet S., Werner A., et al. Probiotics and prebiotics in preventing episodes of acute otitis media in high-risk children: a randomized, double-blind, placebo-controlled study. Pediatr Infect Dis J 2013.
35. Kollef M.H. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med 2004, 32:1396-1405.
36. de Smet A.M.G.A., Kluytmans J.A.J.W., Blok H.E.M., Mascini E.M., Benus R.F.J., Bernards A.T., et al. Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: an open-label, clustered group-randomised, crossover study. Lancet Infect Dis 2011, 11:372-380.
37. Morrow L.E., Kollef M.H. Recognition and prevention of nosocomial pneumonia in the intensive-care unit and infection control in mechanical ventilation. Crit Care Med 2010, 38:S352-S362.
38. Morrow L.E., Kollef M.H., Casale T.B. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med 2010, 182:1058-1064.
39. Forestier C., Guelon D., Cluytens V., Gillart T., Sirot D., De Champs C. Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive-care unit patients. Crit Care 2008, 12:R69.
40. Klarin B., Molin G., Jeppsson B., Larsson A. Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study. Crit Care 2008, 12:R136.
41. Knight D.J.W., Gardiner D., Banks A., Snape S.E., Weston V.C., Bengmark S., et al. Effect of synbiotic therapy on the incidence of ventilator associated pneumonia in critically ill patients: a randomised, double-blind, placebo-controlled trial. Intensive-care Med 2009, 35:854-861.
42. Kotzampassi K., Giamarellos-Bourboulis E.J., Voudouris A., Kazamias P., Eleftheriadis E. Benefits of a synbiotic formula (Synbiotic 2000Forte) in critically Ill trauma patients: early results of a randomized controlled trial. World J Surg 2006, 30:1848-1855.
43. Spindler-Vesel A., Bengmark S., Vovk I., Cerovic O., Kompan L. Synbiotics, prebiotics, glutamine, or peptide in early enteral nutrition: a randomized study in trauma patients. JPEN J Parenter Enteral Nutr 2007, 31:119-126.
44. Barraud D., Blard C., Hein F., Marçon O., Cravoisy A., Nace L., et al. Probiotics in the critically ill patient: a double-blind, randomized, placebo-controlled trial. Intensive Care Med 2010, 36:1540-1547.
45. Salva S., Villena D., Alvarez S. Immunomodulatory activity of Lactobacillus rhamnosus strains isolated from goat milk: impact on intestinal and respiratory infections. Int J Food Microbiol 2010, 141:82-89.
46. Villena D., Medina M., Vintiñi E., Alvarez S. Stimulation of respiratory immunity by oral administration of Lactococcus lactis. Can J Microbiol J 2008, 54:630-638.
47. Hanniffy S.B., Carter A.T., Hitchin E., Wells J.M. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Dis 2007, 195:185-193.
48. Medina M., Villena D., Vintiñi E., Hebert E.M., Raya R., Alvarez S. Nasal immunization with Lactococcus lactis expressing the pneumococcal protective protein A induces protective immunity in mice. Infect Immun 2008, 76:2696-2705.
49. Izumo T., Maekawa T., Ida M., Noguchi A., Kitagawa Y., Shibata H., et al. Effect of intranasal administration of Lactobacillus pentosus S-PT84 on influenza virus infection in mice. Int Immunopharmacol 2010, 10:1101-1106.
50. Maeda N., Nakamura R., Hirose Y., Murosaki S., Yamamoto Y., Kase T., et al. Oral administration of heat-killed Lactobacillus plantarum L-137 enhances protection against influenza virus infection by stimulation of type I interferon production in mice. Int Immunopharmacol 2009, 9:1122-1125.
51. Baron M. A patented strain of Bacillus coagulans increased immune response to viral challenge. Postgrad Med 2009, 121:114-118.
52. Bruzzese E., Raia V., Spagnuolo M.I., Volpicelli M., De Marco G., Maiuri L., et al. Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clin Nutr 2007, 26:322-328.
53. Weiss B., Bujanover Y., Yahav Y., Vilozni D., Fireman E., Efrati O. Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Pediatr Pulmonol 2010, 45:536-540.